Effective treatment of injecting drug users with recently acquired hepatitis C virus infection.

ABSTRACT:

Background & aims

Patients with acute hepatitis C virus (HCV) infection who receive treatment achieve high rates of sustained virologic response (SVR), but few studies have examined outcomes among injecting drug users (IDUs). We evaluated the efficacy of treatment of recent HCV infection in IDUs with acute and early chronic HCV.

Methods

We analyzed data from the Australian Trial in Acute Hepatitis C-a prospective study of the natural history and treatment outcomes of patients with recent HCV infection. Participants eligible for the study had their first anti-HCV antibody-positive test result within the past 6 months and either acute clinical HCV within the past 12 months or documented anti-HCV seroconversion within 24 months. Participants with HCV received pegylated interfer

SUBMITTER: Dore GJ 

PROVIDER: S-EPMC2813391 | biostudies-literature | 2010 Jan

REPOSITORIES: biostudies-literature